Abstract library

1015 results for "intra-arterial radionuclide treatment".
#71 Treatment of unresectable neuroendocrine liver tumors with Y-90 microsphere
Introduction: The primary therapy of liver lesions of NET is surgery but it is most possible for all patients. Selective internal radiation therapy (SIRT) is a newly available method to treats liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Seda Lacin
#1456 Retreatment with Peptide-Receptor Radionuclide Therapy: Effects on Long-term Survival, Renal and Bone Marrow Toxicity Using Yttrium-90 vs. Lutetium-177
Introduction: PRRT is an effective treatment for metastatic NETs. The effect of PRRT retreatment is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Joseph Machta
Keywords: PRRT, retreatment
#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#1898 Over Treatment Radionuclide Therapy (PRRT) of Metastatic Neuroendocrine Neoplasm (NEN) – A Case Report.
Introduction: Over treatment radionuclide therapy (PRRT) of metastatic neuroendocrine neoplasm (NEN).
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Karolina Poczkaj
#2023 International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors
Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Arthur Braat
#252 Y90-DOTATATE in Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Survival Following Different Indications for Treatment
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an increasingly used treatment for GEP -NETs but there is limited data on indications, efficacy and survival.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Giovanni Paganelli
#358 Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.
Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.
Conference:
Category: Basic
Presenting Author: Dr Andrew Mallia
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.